marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-12-2024
Corvus Pharmaceuticals Balance Sheet 2011-2024 | CRVS
Annual Balance Sheet Corvus Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-10.6 M | -59.8 M | - | -1.97 M | -39.2 M | -45.1 M | -5.05 M | -4.1 M | -9.92 M | - | - | - | |
Long Term Debt |
- | 1.37 M | 2.6 M | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
1.37 M | 1.23 M | 1.05 M | 1.08 M | 878 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 2.31 M | 869 K | 971 K | 1.4 M | 126 M | 10 M | - | - | - |
Total Current Liabilities |
6.87 M | 10.8 M | 9.69 M | 12.1 M | 10.2 M | 7.03 M | 8.97 M | 5.94 M | - | - | - | - | - |
Total Liabilities |
6.87 M | 12.1 M | 12.3 M | 13.4 M | 12.5 M | 7.9 M | 9.94 M | 7.35 M | 130 M | 12.7 M | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-335 M | -308 M | -266 M | -223 M | -217 M | -170 M | -124 M | -67.9 M | -31.5 M | -161 K | - | - | - |
Total Assets |
45.6 M | 68.2 M | 109 M | 85.5 M | 83.6 M | 118 M | 94.8 M | 140 M | 98.5 M | 12.5 M | - | - | - |
Cash and Cash Equivalents |
12.6 M | 13.2 M | 63.5 M | 16.5 M | 5.15 M | 39.2 M | 45.1 M | 5.05 M | 4.1 M | 12.5 M | - | - | - |
Book Value |
38.7 M | 56.1 M | 97.2 M | 72.1 M | 71.1 M | 110 M | 84.8 M | 133 M | -31.1 M | -159 K | - | - | - |
Total Shareholders Equity |
38.7 M | 56.1 M | 97.2 M | 72.1 M | 71.1 M | 110 M | 84.8 M | 133 M | -31.1 M | -159 K | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Corvus Pharmaceuticals
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | 354 K | 700 K | 1.04 M | 1.37 M | 1.69 M | 2 M | 2.3 M | 2.6 M | 2.87 M | 631 K | 935 K | 1.23 M | 1.23 M | 1.23 M | 1.23 M | 2.31 M | 2.31 M | 2.31 M | 2.31 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
46.4 M | 13.3 M | 6.72 M | 6.87 M | 7.65 M | 8.56 M | 9.33 M | 12.1 M | 15.7 M | 12.2 M | 11.6 M | 12.3 M | 14.2 M | 13 M | 14.9 M | 13.4 M | 13.4 M | 13.4 M | 13.4 M | 12.5 M | 12.5 M | 12.5 M | 12.5 M | 7.9 M | 7.9 M | 7.9 M | 7.9 M | 9.94 M | 9.94 M | 9.94 M | 9.94 M | 7.35 M | 7.35 M | 7.35 M | 7.35 M | 3.78 M | 3.78 M | 3.78 M | 3.78 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-385 M | -345 M | -340 M | -335 M | -328 M | -322 M | -316 M | -308 M | -298 M | -283 M | -275 M | -266 M | -257 M | -246 M | -235 M | -223 M | -223 M | -223 M | -223 M | -217 M | -217 M | -217 M | -217 M | -170 M | -170 M | -170 M | -170 M | -124 M | -124 M | -124 M | -124 M | -67.9 M | -67.9 M | -67.9 M | -67.9 M | -31.5 M | -31.5 M | -31.5 M | -31.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
58.8 M | 64.6 M | 40.1 M | 45.6 M | 51.9 M | 58 M | 58.2 M | 68.2 M | 80.3 M | 92.5 M | 101 M | 109 M | 119 M | 109 M | 109 M | 85.5 M | 85.5 M | 85.5 M | 85.5 M | 83.6 M | 83.6 M | 83.6 M | 83.6 M | 118 M | 118 M | 118 M | 118 M | 94.8 M | 94.8 M | 94.8 M | 94.8 M | 140 M | 140 M | 140 M | 140 M | 98.5 M | 98.5 M | 98.5 M | 98.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
4.68 M | 14.8 M | 7.46 M | 12.6 M | 20.1 M | 7.66 M | 9.65 M | 13.2 M | 24.6 M | 28.5 M | 31.5 M | 63.5 M | 72.3 M | 58.9 M | 45.1 M | 16.5 M | 16.5 M | 16.5 M | 16.5 M | 5.15 M | 5.15 M | 5.15 M | 5.15 M | 39.2 M | 39.2 M | 39.2 M | 39.2 M | 45.1 M | 45.1 M | 45.1 M | 45.1 M | 5.05 M | 5.05 M | 5.05 M | 5.05 M | 4.1 M | 4.1 M | 4.1 M | 4.1 M | 12.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
12.4 M | 51.2 M | 33.4 M | 38.7 M | 44.3 M | 49.5 M | 48.9 M | 56.1 M | 64.7 M | 80.4 M | 89.7 M | 97.2 M | 105 M | 96.4 M | 94.4 M | 72.1 M | 72.1 M | 72.1 M | 72.1 M | 71.1 M | 71.1 M | 71.1 M | 71.1 M | 110 M | 110 M | 110 M | 110 M | 84.8 M | 84.8 M | 84.8 M | 84.8 M | 133 M | 133 M | 133 M | 133 M | 94.7 M | 94.7 M | 94.7 M | 94.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
12.4 M | 51.2 M | 33.4 M | 38.7 M | 44.3 M | 49.5 M | 48.9 M | 56.1 M | 64.7 M | 80.4 M | 89.7 M | 97.2 M | 105 M | 96.4 M | 94.4 M | 72.1 M | 72.1 M | 72.1 M | 72.1 M | 71.1 M | 71.1 M | 71.1 M | 71.1 M | 110 M | 110 M | 110 M | 110 M | 84.8 M | 84.8 M | 84.8 M | 84.8 M | 133 M | 133 M | 133 M | 133 M | -31.1 M | -31.1 M | -31.1 M | -31.1 M | -159 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency